Arvinas, Inc. (ARVN)
NASDAQ: ARVN · IEX Real-Time Price · USD
32.37
+0.77 (2.44%)
At close: Apr 26, 2024, 4:00 PM
31.75
-0.62 (-1.92%)
After-hours: Apr 26, 2024, 5:01 PM EDT
Arvinas Revenue
In the year 2023, Arvinas had annual revenue of $78.50M, a decrease of -40.26%. Revenue in the quarter ending December 31, 2023 was $-43.10M, a -214.02% decrease year-over-year.
Revenue (ttm)
$78.50M
Revenue Growth
-40.26%
P/S Ratio
28.17
Revenue / Employee
$176,404
Employees
445
Market Cap
2.21B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.62B |
| Privia Health Group | 1.66B |
| Integra LifeSciences Holdings | 1.54B |
| PTC Therapeutics | 927.56M |
| Tandem Diabetes Care | 747.72M |
| Inari Medical | 493.63M |
| Denali Therapeutics | 330.53M |
| Vericel | 197.52M |
ARVN News
- 2 days ago - Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer - GlobeNewsWire
- 16 days ago - Arvinas inks over $1.0 billion deal with Novartis - Invezz
- 16 days ago - Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer - GlobeNewsWire
- 5 weeks ago - Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arvinas Announces Chief Financial Officer Transition - GlobeNewsWire
- 2 months ago - Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease - GlobeNewsWire